Added to YB: 2026-09-08
Pitch date: 2026-09-05
CLYM [neutral]
Climb Bio, Inc.
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
Market Cap
$891.4M
Pitch Price
N/A
Price Target
21.80 (+40%)
Dividend
N/A
EV/EBITDA
-10.16
P/E
-18.59
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
Can we CLIMB to the top? : An analysis of Climb Bio ($CLYM)
CLYM (monitor): Climb Bio remains a monitor despite a $21.80 rNPV target, 40% above $15.52. Lead drug CLYM116 delivered durable Phase 1 biomarker reductions and quarterly dosing, while $146.3M of cash and no debt provide runway into late 2028. However, healthy-volunteer, open-label data have yet to establish proteinuria efficacy against an approved rival with a multi-year lead; Phase 2 results are the key unresolved proof point.
Read full article (5 min)